
Honorary Geordie, a mum and clinical oncologist (#Radonc+med onc😉). Made in the Northeast, UK. "90% of life is showing up." views are mine - share you may!
United Kingdom
Joined September 2017
- Tweets865
- Following466
- Followers337
- Likes1.9K
Dr XY Jiang (Xj) retweeted
From biology to patient benefit.
CAPItello-281 brings PTEN-targeted therapy closer to clinical reality. Proud to contribute to this research.
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @Annals_Oncology @tompowles1
📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.
🔗shorturl.at/c6tvw
@Daniel_J_George
Dr XY Jiang (Xj) retweeted
#ESMO26 PROTEUS discussion by Nicholas van As
• No baseline PSMA PET; enrolled conventionally staged M0
• MFS events: true progression or delayed detection? Most were PSMA PET-detected (8.8% vs 16.3%)
• TTST HR 0.29, but ~20-mo lead-time bias
#ProstateCancer
Dr XY Jiang (Xj) retweeted
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.
🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
Dr XY Jiang (Xj) retweeted
Six phase III trials. Six different stories.
Higher pCR does not guarantee better survival.
In muscle-invasive bladder cancer, EFS and OS matter more than impressive response rates.
Are we measuring what truly matters to patients?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @urologysummit @Uromigos @Uroweb @urotoday
Dr XY Jiang (Xj) retweeted
Putting STAMPEDE, ENZARAD, PROTEUS & DASL into context with the latest #ESMO26 updates:
STAMPEDE: Abiraterone-based intensification improved MFS AND OS, predominantly with RT. New #ESMO26 Decipher data suggests differential abi benefit in cN0 disease (interaction P=.01); using this to omit treatment still requires validation.
ENZARAD: At 8 years, MFS was 74% vs 72% (HR 0.88; P=.34). No significant overall MFS benefit from enza + ADT/RT. The cN1/planned pelvic RT subgroup signals remain hypothesis-generating.
DASL: new at #ESMO26: 1,106 patients; 96 weeks of daro v. placebo + ADT + prostate/bed AND pelvic RT. Four-year conventional-imaging MFS: 95% vs 88% (HR 0.42). Very-high-risk population, including selected postoperative patients. Interim analysis; OS immature.
PROTEUS main trial: Perioperative apa + ADT improved 5-year PSMA-inclusive MFS versus ADT alone: 78.2% vs 73.5% (HR 0.80). Conventional-imaging MFS was not statistically significant. #ESMO26 post hoc PSA-response analysis adds prognostic information.
PROTEUS randomized substudy: new at #ESMO26: Perioperative apa/ADT + RP/PLND (n=102) v. immediate RP/PLND (n=306). At 37.8 months’ follow-up:
• 3-year EFS: 63.0% vs 41.4%; HR 0.38.
• Secondary PSMA-inclusive MFS: HR 0.49; nominal P=.0193.
• Subsequent postoperative RT: 20% vs 43%.
The substudy strengthens a "perioperative strategy". But conventional-imaging entry followed by PSMA-inclusive endpoints matters. PSA-based EFS, conventional MFS and PSMA-inclusive MFS are different endpoints.
These trials support specific intensification strategies; they cannot rank the drugs or establish RP-versus-RT superiority. The decision remains who benefits enough to justify the ENTIRE treatment burden.
Dr XY Jiang (Xj) retweeted
💔 EV has a new partner!
PEMBRO: “Another checkpoint inhibitor?!” 😳
EV: “We have survival data TOO!” ❤️
🔥 VOLGA | ESMO 2026
EFS HR 0.51 | OS HR 0.58
But PEMBRO isn't out of the picture!
KEYNOTE-905: EFS HR 0.40 | OS HR 0.50
Two promising perioperative partnerships in cisplatin-ineligible MIBC.
⚠️ Different trials. No head-to-head comparison.
@myESMO @OncoAlert #MVOnco #ESMO2026 #BladderCancer
Dr XY Jiang (Xj) retweeted
⚡️ Phase 2 trial in RCC with inferior vena cava tumor thrombus: neoadjuvant stereotactic ablative radiotherapy (SAbR) followed by surgery (n=23).
1-year recurrence-free survival: 71.4% — above the 55.7% historical benchmark. Thrombus downstaging in 22%.
A promising approach for one of the most challenging complications in kidney cancer.
#KidneyCancer #RCC @JAMAOnc
jamanetwork.com/journals/jam…
Dr XY Jiang (Xj) retweeted
Are we underestimating aggressive prostate cancer by missing its most important histological warning signs?
nature.com/articles/s41585-0…
Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Intraductal carcinoma of the prostate (IDC) 🔬 and invasive cribriform carcinoma are aggressive histological patterns associated with adverse pathology, metastasis, and prostate cancer mortality.
➡️ Frequently underdetected on biopsy, they exhibit PTEN loss, genomic instability, DNA-repair alterations, and immunologically cold tumour microenvironments.
➡️ Although these features suggest potential biomarker-directed therapies, evidence remains insufficient.
✅ Standardized reporting, improved detection, and prospective studies are essential to guide risk stratification and treatment decisions. #ProstateCancer
@ruimmbernardino, @JoaoPedroLobo89, @ZSchwen, @Adam_Weiner535, @JaneNguyen44, @NicolasSoputro, @GhandourRashed, @TunaBeksac, @KarimDaherMD, @roodvdb, @GMarra_MD, @FalzarsMd, @DrCristinaMagi, @cosimodenunzio, @FleshnerNeil, @Dr_JihadKaouk, @ricautor
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Dr XY Jiang (Xj) retweeted
🚨 New review in @NatRevUrol 🚨
🔬Cribriform & intraductal carcinoma (IDC) of the prostate: the high-risk histology
@ruimmbernardino
🧬 IDC + invasive cribriform independently predict adverse path, mets & PCa death,
🔎 Biopsy catches them in only ~half of men who harbor them, and MRI targeting doesn't close the gap
📈 Prevalence climbs w/ risk: ~2% in low-risk to >50% in metastatic/recurrent
🧪 Enriched for PTEN loss, DDR alterations, genomic instability & an immune-cold, fibroblast-rich niche
🎯 Bottom line: It should be reported and more is to come on how it should factor into decision making
🔗 doi.org/10.1038/s41585-026-0…
@AmerUrological @UroOnc @urotoday @UrologyTimes @PCF_Science
Dr XY Jiang (Xj) retweeted
⚡️ 3–5% of all renal cell carcinomas are hereditary — yet most patients are never tested.
While germline testing is standard in breast, ovarian and colorectal cancer, a significant gap remains in urological malignancies despite the actionability of hereditary RCC syndromes.
Time to close that gap.
europeanurology.com/article/…
@EuropeanUrology #KidneyCancer
Dr XY Jiang (Xj) retweeted
☢️ #ASTRO26: LDRT in knee OA is fascinating.
292 patients | 4.5 Gy/10 fractions
At 3 years:
🦵 VAS pain: 21 vs 55
📈 Responders: 69% vs 25% (p<0.0001)
Long-term: disability 14% vs 25%; KL-2 knee replacement 14% vs 36% (HR 0.32, p=0.021).
Dr XY Jiang (Xj) retweeted
Virtually walking the halls at #ASTRO2026 as a medical oncologist, I keep coming back to the same thought: radiation oncology is quietly rewriting what “definitive local therapy” can look like.
The unveiling of Accela from @SiemensHealthineers is more than another linac. Single-breath-hold SBRT, multi-site treatments in ~60 seconds, imaging-to-beam-off in under 90 seconds. Speed that actually changes biology and logistics, not just throughput. Patients spend less time on the table. Targets have less chance to move. Adaptive workflows become practical rather than aspirational.
What strikes me most as a simple.medonc is the accumulating evidence that SBRT is matching surgery in more and more settings: early lung cancer, localized prostate (PACE-A data here this week), selected oligometastases, small HCC. Every time we add a tumor type to that list, we spare someone anesthesia, a wound, weeks of recovery, and the cascade of complications that still follow even “minimally invasive” operations.
Surgery will always have its place. But the risk-benefit conversation is shifting. For older, frail, or multi-morbid patients, the ones I see every clinic day, the non-invasive option is no longer a consolation prize. It is often the more thoughtful one.
The field is not just getting more precise. It is getting faster, smarter, and more humane. That is worth paying attention to, even from the medical oncology side of the hallway. Well done my fellow radoncs!!
Dr XY Jiang (Xj) retweeted
Cancer care is changing because more people are surviving.
~18.6M survivors in the US in 2025.
~22.3M projected by 2035.
The next challenge is not only helping people live longer, but helping them live better.
@CACancerJournal @OncoAlert @OpenMedicineHQ @ASCO @AmericanCancer
Dr XY Jiang (Xj) retweeted
#ASTRO26
@angela_jia_ and team bringing the 🔥 with incredibly important data.
Translational study of @NRGonc RTOG 0815 showing Decipher was prognostic and predictive and those with lower decipher do benefit from ADT with RT.
#pcsm @TylerSbrt @urotoday @DrChoueiri @AmarUKishan @DrHowardSandler @MutlaySayan @jmmrad @ASTRO_org @NehaVapiwala
Dr XY Jiang (Xj) retweeted
Importantly this is modern data that with a spacer gel and SBRT at 2 years 80% of men remain potent.
This is in a prospective RCT with patient reported outcomes.
🧐nerve-sparing prostate RT?
@ndesai2005 presents Poten-C trial
Unilateral NVB sparing:
❌ did not improve sexual function (primary endpoint)
🤔 urinary function better w NVB sparing
@ASTRO_org #ASTRO26
Dr XY Jiang (Xj) retweeted
INTREPId at #ASTRO26: a fascinating result.
Darolutamide + RT preserved good erectile function far better than ADT + RT (71.9% vs 43.6%), BUT had slightly worse early PSA suppression (90.8% vs 99.1%).
The clinical relevance? Likely nothing given different mechanism of action.
3- to 5-yr PSA control even is a weak endpoint...PSA suppression is even weaker.
@ASTRO_org @TylerSbrt #pcsm @HimanshuNagarMD @angela_jia_ @DocJarad @DrAndrewLoblaw @Adam_Weiner535 @alison_tree @jryckman3 @Soum_Roy_RadOnc @jamesbyu @urotoday @rtdess @ndesai2005
Dr XY Jiang (Xj) retweeted
Across 3 prospective studies, the signal for post-prostatectomy SBRT in 5 fx is increasingly consistent: feasible, low toxicity & excellent in-field control. StereoBed randomized data show no PRO/toxicity penalty; POPART/esSBRT show few local failures.
#ASTRO26 @rtdess @HimanshuNagarMD @RadOncDocJ @NRGonc @ASTRO_org @urotoday @ChadTangMD @TylerSbrt @SbrtSean @jryckman3 @seanmmcbride

















































